Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart, Inovio, and Sorrento Therapeutics Stocks Soared Thursday

By Joe Tenebruso - Updated Jun 26, 2020 at 7:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are piling into coronavirus stocks as COVID-19 cases surge.

What happened

The war against COVID-19 is intensifying, and investors are placing their bets on which companies they believe will emerge victorious. Shares of Vaxart (VXRT 4.38%), Inovio Pharmaceuticals (INO -0.42%), and Sorrento Therapeutics (SRNE 0.36%) rocketed 96%, 31%, and 14%, respectively, on Thursday.

So what

Vaxart's shares almost doubled after the biotech company announced a "memorandum of understanding" with Attwill Medical Solutions (AMS) for the potential production of its experimental oral COVID-19 vaccine for the SARS-CoV-2 virus. 

"We believe AMS' experience coupled with its ability to manufacture a billion or more doses per year would be a beneficial addition to our group of [contract development and manufacturing organization] partners, and enable the large scale manufacturing and ultimate supply of our COVID-19 vaccine for the U.S., Europe, and other countries in need," Vaxart CEO Andrei Floroiu said in a press release.

A person is pointing to three upwardly sloping lines on a chart.

COVID-19 stocks surged on Thursday. Image source: Getty Images.

Vaxart says that its vaccine, which is administered by tablet rather than injection, has multiple advantages over other vaccine candidates being developed by its competitors.

"We believe our oral vaccines, generated on our proven platform, have the potential to offer superior protection against airborne viruses such as SARS-CoV-2 by triggering both mucosal and systemic immunity while being administered by a room-temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns," Floroiu said.

Inovio, meanwhile, announced that it was expanding its executive team. Gene Kim, who brings with him experience as CFO for multiple public companies, will be tasked with driving Inovio's growth in Asia. Dr. Mammen (Anza) Mammen, who previously was chief of the Pandemic Warning Team for the U.S. Department of Defense, will help lead the company's clinical development operations. 

Sorrento likely rose as investors placed bets that surging coronavirus case counts worldwide would increase the likelihood its experimental antibodies treatment is approved for emergency use by health authorities. The biopharmaceutical company says the treatment can neutralize the coronavirus.  

Now what 

If coronavirus infections continue to rise at an alarming rate, more money will likely flow into companies that are working to develop vaccines and treatments. Yet, with more than 100 companies competing to be the first to find a panacea for the crisis, it's difficult to know which will ultimately win the race.

Thus, while they're promising not only for their potential investment merits but also for the good they can do for humanity, Vaxart, Inovio Pharmaceuticals, and Sorrento Therapeutics should be considered high-risk stocks.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$2.36 (-0.42%) $0.01
Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
$2.77 (0.36%) $0.01
Vaxart, Inc. Stock Quote
Vaxart, Inc.
$4.29 (4.38%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.